GlassScriptPhysician profile
Richard Ankrah
NPI 1174038400
$3,597.78
in general payments reported to CMS, 2019-2025
27 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $467 · 2022: $955 · 2023: $910 · 2024: $1,163 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,175.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $950.71 | 2021-2024 | |
| Gilead Sciences, INC. | $496.94 | 2021-2024 | |
| Viiv Healthcare Company | $334.15 | 2023-2024 | Dovato |
| Astrazeneca Pharmaceuticals LP | $235.23 | 2021-2024 | Breztri, Farxiga, Fasenra |
| Pfizer INC. | $226.28 | 2022-2024 | |
| Glaxosmithkline, LLC. | $204.72 | 2021-2025 | Arexvy, Shingrix, Bexsero |
| Lilly USA, LLC | $163.65 | 2022-2024 | Mounjaro |
| Abbott Laboratories | $161.83 | 2024 | Esprit |
| Biohaven Pharmaceutical Holding Company LTD. | $114.55 | 2022 | |
| Novo Nordisk INC | $101.54 | 2022 | |
| Sanofi-Aventis U.S. LLC | $79.12 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.72 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.45 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $41.89 | 2023-2024 | Rexulti |
| Shield Therapeutics INC | $38.81 | 2022-2023 | Accrufer |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $38.41 | 2021-2023 | Pifeltro, Delstrigo |
| Edwards Lifesciences Corporation | $37.66 | 2022-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Bayer Healthcare Pharmaceuticals INC. | $37.33 | 2022-2023 | |
| Corcept Therapeutics | $37.03 | 2023 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.69 | 2021-2023 | Jardiance, Synjardy |
| Amgen INC. | $34.14 | 2021-2023 | Repatha, Otezla |
| Daiichi Sankyo INC. | $24.73 | 2024 | Injectafer |
| Exact Sciences Corporation | $22.62 | 2024 | Cologuard Collection Kit |
| Dexcom, INC. | $20.21 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $17.35 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.24 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.78 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Ankrah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.